The 16,141 Shares of Nektar Therapeutics (NKTR) are sold by UBS Asset Management Americas Inc.

The 16,141 Shares of Nektar Therapeutics (NKTR) are sold by UBS Asset Management Americas Inc.

UBS Asset Management Americas Inc. decreased its position in Nektar Therapeutics (NASDAQ:NKTR) by 12.2% during the second quarter, Holdings Channel reports. The firm owned 116,124 shares of the biopharmaceutical company’s stock after selling 16,141 shares during the period. UBS Asset Management Americas Inc. owned 0.08% of Nektar Therapeutics worth $1,652,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the company. Prudential Financial Inc. increased its stake in Nektar Therapeutics by 4.9% in the first quarter. Prudential Financial Inc. now owns 322,973 shares of the biopharmaceutical company’s stock worth $4,441,000 after buying an additional 15,100 shares during the period. BlackRock Inc. increased its stake in Nektar Therapeutics by 74.8% in the first quarter. BlackRock Inc. now owns 9,013 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 3,858 shares during the period. BlackRock Group LTD increased its stake in Nektar Therapeutics by 8.9% in the first quarter. BlackRock Group LTD now owns 175,205 shares of the biopharmaceutical company’s stock worth $2,408,000 after buying an additional 14,340 shares during the period. BlackRock Fund Advisors increased its stake in Nektar Therapeutics by 1.7% in the first quarter. BlackRock Fund Advisors now owns 10,029,475 shares of the biopharmaceutical company’s stock worth $137,905,000 after buying an additional 171,759 shares during the period. Finally, State Street Corp increased its stake in Nektar Therapeutics by 4.5% in the first quarter. State Street Corp now owns 3,480,120 shares of the biopharmaceutical company’s stock worth $47,852,000 after buying an additional 151,371 shares during the period. 96.91% of the stock is currently owned by institutional investors and hedge funds.

Shares of Nektar Therapeutics (NASDAQ:NKTR) traded up 0.72% on Wednesday, hitting $16.76. The stock had a trading volume of 67,115 shares. The company has a 50 day moving average of $18.11 and a 200-day moving average of $16.00. Nektar Therapeutics has a 12-month low of $9.92 and a 12-month high of $19.98. The firm’s market capitalization is $2.29 billion.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.03. Nektar Therapeutics had a negative net margin of 68.30% and a negative return on equity of 8,769.15%. The company earned $32.77 million during the quarter, compared to the consensus estimate of $34.17 million. During the same period last year, the firm posted ($0.40) earnings per share. The company’s revenue for the quarter was up 44.6% on a year-over-year basis. Equities analysts predict that Nektar Therapeutics will post ($1.11) EPS for the current fiscal year.

A number of research firms have weighed in on NKTR. Zacks Investment Research raised Nektar Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 price objective on the stock in a report on Tuesday, July 19th. Brean Capital reaffirmed a “buy” rating and set a $18.00 price objective on shares of Nektar Therapeutics in a report on Friday, August 5th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $21.00 price objective (up from $17.00) on shares of Nektar Therapeutics in a report on Friday, August 5th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Nektar Therapeutics in a report on Thursday, September 8th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $21.75.

In other news, Director Robert Chess sold 5,000 shares of Nektar Therapeutics stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $17.26, for a total transaction of $86,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Howard W. Robin sold 11,817 shares of Nektar Therapeutics stock in a transaction dated Tuesday, August 16th. The shares were sold at an average price of $17.56, for a total transaction of $207,506.52. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by company insiders.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

Related posts

Leave a Comment